Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:ATCCode |
L02BX06
|
| gptkbp:CASNumber |
737789-87-6
|
| gptkbp:chemicalFormula |
C29H27F2N7O5
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:relugolix
|
| https://www.w3.org/2000/01/rdf-schema#label |
Orgovyx
|
| gptkbp:indication |
prostate cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Myovant_Sciences
|
| gptkbp:mechanismOfAction |
GnRH receptor antagonist
|
| gptkbp:pregnancyCategory |
not for use in women
|
| gptkbp:prescribes |
advanced prostate cancer
hormone-sensitive prostate cancer |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
musculoskeletal pain hot flush decreased hemoglobin |
| gptkbp:status |
FDA approved
|
| gptkbp:synonym |
gptkb:TAK-385
|
| gptkbp:bfsParent |
gptkb:Myovant_Sciences
gptkb:relugolix |
| gptkbp:bfsLayer |
6
|